UK Pharma’s Golden Ticket: How Tariff-Free Access to the US Reshapes Investment

The UK pharmaceutical industry has just been handed a golden ticket: tariff-free access to the US market. This landmark agreement, the only one of its kind in the world, has the potential to reshape investment strategies and solidify the UK’s position as a global life sciences leader. But what does this deal really mean for the industry, the NHS, and patients?

The Transatlantic Shift: A New Era for UK Pharma

For decades, the transatlantic pharmaceutical landscape operated under predictable norms. The US accepted higher drug prices in exchange for early access and a strong domestic industry, while the UK and Europe relied on external reference pricing and health technology assessment to negotiate favorable prices. Trade policies reinforced this equilibrium through tariff-free movement of medicines.

However, the game has changed. The US has begun to reactivate “Most-Favored-Nation” (MFN) pricing and introduce tariffs on selected branded medicines, creating direct exposure to US policy choices for the UK and Europe. These shifts are compressing the traditional transatlantic price gap, altering launch strategies, and reshaping global competition for manufacturing investment.

The Golden Ticket: Zero Tariffs to the US

In a significant win for the UK, the US has agreed to a zero percent tariff on all UK pharmaceutical exports for at least three years. This preferential rate, the lowest offered to any country, provides a distinct advantage for UK-based manufacturers. According to the UK government, this deal guarantees that UK pharmaceutical exports, worth at least £5 billion a year, will enter the US tariff-free, protecting jobs, boosting investment, and paving the way for the UK to become a global hub for life sciences. In 2024, UK exports to the US were worth more than £59 billion, 16% of all UK goods exports. Medicinal and pharmaceutical products accounted for £11.1 billion of that total.

This agreement also extends to medtech exports, ensuring no additional tariffs and unlocking further investments in the UK. Major firms like Moderna, Bristol Myers Squibb, and BioNTech have already invested billions in the UK, signaling renewed confidence in the UK’s life sciences sector.

The NHS Commitment: Investing in Innovation

In exchange for tariff-free access to the US market, the UK government has committed to increasing investment in innovative, safe, and effective treatments by around 25%. This represents the first major increase in over two decades and will be implemented through changes to the National Institute for Health and Care Excellence (NICE) cost-effectiveness thresholds.

Specifically, NICE will be able to approve medicines that deliver significant health improvements but might have previously been declined purely on cost-effectiveness grounds. This could include breakthrough cancer treatments, therapies for rare diseases, and innovative approaches to conditions that have previously been difficult to treat. The baseline QALY threshold under which NICE considers new treatments to be cost-effective when assessed against current available treatments will be uplifted, from £20,000-£30,000 to £25,000-£35,000.

The government will also apply “a new value set for valuing health-related quality of life”, following consultation, while the deal also places a 15% cap on the rebates branded medicines suppliers are required to pay to the NHS when the total NHS bill for those products exceeds the growth rates provided for under the voluntary scheme for branded medicines pricing, access and growth (VPAG).

Reshaping Investment: A Magnet for Life Sciences

The zero-tariff deal is expected to have a significant impact on investment in the UK pharmaceutical industry. By removing trade barriers and solidifying the UK’s position as a global life sciences hub, the agreement is likely to attract further investment in research, development, and manufacturing.

Bristol Myers Squibb (BMS), for example, anticipates investing upwards of $500 million over the next 5 years across multiple areas of its business, including research, development, and manufacturing, based on the UK’s commitments and increased investment in innovative medicines.

However, it’s important to note that the UK has been facing increasing competition for pharmaceutical investment in recent years. Since 2018, UK Pharmaceutical R&D investment has underperformed against global trends, with a significant slowdown starting in 2020. Life sciences foreign direct investment into the UK was around 58% lower in 2023 (£795 million) than in 2017 (£1,893 million). The UK’s ranking among comparator countries fell from a high of 2nd in 2017.

The zero-tariff deal with the US could help reverse this trend and make the UK a more attractive destination for pharmaceutical investment.

Challenges and Considerations

While the zero-tariff deal is a positive development for the UK pharmaceutical industry, there are also challenges and considerations to keep in mind.

NHS Affordability: The commitment to increase NHS spending on medicines by 25% will put pressure on healthcare funding, particularly at a time when the NHS is already facing workforce shortages, elective backlogs, and rising demand. Decisions on prioritization will be unavoidable, and the impact will be felt across commissioning, prescribing, and service delivery.
Generic and Biosimilar Manufacturers: A sustained shift towards premium-priced innovation could place pressure on generic and biosimilar manufacturers, reducing competitive tension and potentially driving longer-term price inflation. It is important that manufacturers of generic and biosimilar medicines should not be “squeezed” at the expense of that uplift.
Global Competition: Global competition for clinical trials, launch sequencing, and advanced therapies is intensifying. The UK must therefore avoid complacency and continue to improve its regulatory environment, R&D incentives, and access to funding.

Navigating the Regulatory Landscape

For US companies looking to enter the UK pharmaceutical market, it’s important to understand the regulatory landscape. While both the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) aim to ensure drug safety and efficacy, there are notable differences in their regulatory approaches. The regulatory pathway in the US is often considered more lengthy and stringent, with a focus on extensive clinical trials. In contrast, the MHRA’s approach is generally more streamlined.

The Road Ahead: A Call to Action

The UK’s zero-tariff access to the US market is a golden opportunity to reshape investment, drive innovation, and improve patient outcomes. However, realizing this potential will require a collaborative effort from industry, government, and the NHS.

Industry: Pharmaceutical companies must seize the opportunity to invest in UK research, development, and manufacturing, and to bring innovative medicines to UK patients as quickly as possible.
Government: The government must continue to improve the UK’s regulatory environment, R&D incentives, and access to funding, and to work with industry to address the challenges facing the NHS.
NHS: The NHS must find ways to balance the need to invest in innovative medicines with the need to maintain affordability and ensure access to care for all patients.

By working together, the UK can leverage its golden ticket to create a thriving pharmaceutical industry that benefits patients, the economy, and the world.